MA33751B1 - Composés de spiropipéridine en tant qu'antagonistes de récepteur orl-1 - Google Patents

Composés de spiropipéridine en tant qu'antagonistes de récepteur orl-1

Info

Publication number
MA33751B1
MA33751B1 MA34869A MA34869A MA33751B1 MA 33751 B1 MA33751 B1 MA 33751B1 MA 34869 A MA34869 A MA 34869A MA 34869 A MA34869 A MA 34869A MA 33751 B1 MA33751 B1 MA 33751B1
Authority
MA
Morocco
Prior art keywords
orl
compounds
treatment
spirobridine
receptor antagonists
Prior art date
Application number
MA34869A
Other languages
Arabic (ar)
English (en)
Inventor
Collado Ana Belen Benito
Buezo Nuria Diaz
Alma Maria Jimenez-Aguado
Blanco Celia Lafuente
Maria Angeles Martinez-Grau
Concepcion Pedregal-Tercero
Escribano Miguel Angel Toledo
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MA33751B1 publication Critical patent/MA33751B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/20—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention concerne un antagoniste de récepteur orl-1 de formule i, ses utilisations et procédés de préparation. Des antagonistes de orl-1 sont jugés utiles dans le traitement de la dépression et/ou le traitement du surpoids, de l'obésité, et/ou le maintien du poids après un traitement du surpoids ou de l'obésité. Certains composés ont également montré dans des modèles animaux que les composés de la présente invention sont utiles pour le traitement de migraines.
MA34869A 2009-11-16 2012-05-14 Composés de spiropipéridine en tant qu'antagonistes de récepteur orl-1 MA33751B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09382246 2009-11-16
US29862910P 2010-01-27 2010-01-27
PCT/US2010/056180 WO2011060035A1 (fr) 2009-11-16 2010-11-10 Composés de spiropipéridine en tant qu'antagonistes de récepteur orl-1

Publications (1)

Publication Number Publication Date
MA33751B1 true MA33751B1 (fr) 2012-11-01

Family

ID=41728051

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34869A MA33751B1 (fr) 2009-11-16 2012-05-14 Composés de spiropipéridine en tant qu'antagonistes de récepteur orl-1

Country Status (34)

Country Link
US (1) US8232289B2 (fr)
EP (1) EP2501703B1 (fr)
JP (1) JP5680101B2 (fr)
KR (1) KR101363830B1 (fr)
CN (1) CN102612520B (fr)
AR (1) AR078863A1 (fr)
AU (1) AU2010319581C1 (fr)
CA (1) CA2796161C (fr)
CO (1) CO6541545A2 (fr)
CR (1) CR20130087A (fr)
DK (1) DK2501703T3 (fr)
DO (1) DOP2012000135A (fr)
EA (1) EA020848B1 (fr)
EC (1) ECSP12011902A (fr)
ES (1) ES2435814T3 (fr)
HN (1) HN2012001011A (fr)
HR (1) HRP20130967T1 (fr)
IL (1) IL219370A (fr)
JO (1) JO2887B1 (fr)
MA (1) MA33751B1 (fr)
ME (1) ME01537B (fr)
MX (1) MX2012005691A (fr)
MY (1) MY160665A (fr)
NZ (1) NZ600006A (fr)
PE (1) PE20121430A1 (fr)
PH (1) PH12012500969A1 (fr)
PL (1) PL2501703T3 (fr)
PT (1) PT2501703E (fr)
RS (1) RS53018B (fr)
SI (1) SI2501703T1 (fr)
TW (1) TWI465453B (fr)
UA (1) UA107943C2 (fr)
WO (1) WO2011060035A1 (fr)
ZA (1) ZA201202967B (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3252057T (pt) 2009-12-04 2024-06-04 Sunovion Pharmaceuticals Inc Compostos multicíclicos e métodos de utilização dos mesmos
US9394290B2 (en) * 2010-10-21 2016-07-19 Universitaet Des Saarlandes Campus Saarbruecken Selective CYP11B1 inhibitors for the treatment of cortisol dependent diseases
TWI582096B (zh) * 2011-12-06 2017-05-11 美國禮來大藥廠 用於酒精依賴及濫用處理之４',５'－二氫螺［哌啶－４,７'－噻吩并[２，３－c]哌喃］化合物
TW201416370A (zh) 2012-07-31 2014-05-01 Lilly Co Eli 用於治療焦慮之ｏｒｌ－１受體拮抗劑
ES2651074T3 (es) 2012-10-02 2018-01-24 Bayer Cropscience Ag Compuestos heterocíclicos como plaguicidas
WO2014078568A1 (fr) 2012-11-14 2014-05-22 The Johns Hopkins University Méthodes et compositions pour le traitement de la schizophrénie
TW201607923A (zh) 2014-07-15 2016-03-01 歌林達有限公司 被取代之氮螺環（４．５）癸烷衍生物
JO3638B1 (ar) * 2015-09-09 2020-08-27 Lilly Co Eli مركبات مفيدة في تثبيط ror - جاما- t
MX2019000982A (es) 2016-07-29 2019-07-04 Sunovion Pharmaceuticals Inc Compuestos y composiciones y usos de los mismos.
EA201990400A1 (ru) 2016-07-29 2019-07-31 Суновион Фармасьютикалз, Инк. Соединения и композиции и их применение
CN116808023A (zh) 2017-02-16 2023-09-29 桑诺维恩药品公司 治疗精神分裂症的方法
US10603320B2 (en) * 2017-03-02 2020-03-31 Eli Lilly And Company Compounds useful for inhibiting ROR-gamma-t
HUE054483T2 (hu) 2017-03-02 2021-09-28 Lilly Co Eli ROR-gamma-T gátlására alkalmas vegyületek
JP7191085B2 (ja) 2017-08-02 2022-12-16 サノビオン ファーマシューティカルズ インク イソクロマン化合物およびその使用
MX2020008537A (es) 2018-02-16 2021-01-08 Sunovion Pharmaceuticals Inc Sales, formas cristalinas y metodos de produccion de las mismas.
IL283592B2 (en) 2018-12-17 2025-08-01 Vertex Pharma Inhibitors of apol1 and methods of using same
CN113784755B (zh) 2019-03-14 2024-05-10 赛诺维信制药公司 异色满基化合物的盐及其结晶形式、制备方法、治疗用途和药物组合物
CA3180115A1 (fr) 2020-04-14 2021-10-21 Sunovion Pharmaceuticals Inc. (s)-(4,5-dihydro-7 h-thieno[2,3-c]pyran-7-yl)-n-methylmethanamine pour le traitement de troubles neurologiques et psychiatriques
EP4165036A1 (fr) 2020-06-12 2023-04-19 Vertex Pharmaceuticals Incorporated Formes solides d'un inhibiteur d'apol1 et utilisation de celles-ci
UY39395A (es) 2020-08-26 2022-03-31 Vertex Pharma Inhibidores de apol1 y métodos para usar los mismos
CA3251050A1 (fr) * 2022-02-08 2023-08-17 Vertex Pharmaceuticals Incorporated Dérivés de 2-méthyl-4',5'-dihydrospiro[pipéridine-4,7'-thiéno[2,3-c]pyran] utilisés en tant qu'inhibiteurs de apol1 et leurs procédés d'utilisation

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL96507A0 (en) 1989-12-08 1991-08-16 Merck & Co Inc Nitrogen-containing spirocycles and pharmaceutical compositions containing them
US6686370B2 (en) 1999-12-06 2004-02-03 Euro-Celtique S.A. Triazospiro compounds having nociceptin receptor affinity
DK1385515T3 (da) 2001-04-18 2008-10-27 Euro Celtique Sa Spiropyrazole forbindelser
WO2002088089A1 (fr) 2001-04-19 2002-11-07 Banyu Pharmaceutical Co., Ltd. Derives de spiropiperidine, antagonistes du recepteur de nociceptine les contenant en tant qu'ingredient actif et compositions medicinales
EP1420020B1 (fr) 2001-07-23 2008-05-28 Banyu Pharmaceutical Co., Ltd. Derive de 4-oxoimidazolidine-2-spiropiperidine
CA2466915A1 (fr) * 2002-01-28 2003-08-07 Pfizer Inc. Composes spiropiperidine n-substitues utilises comme ligands pour le recepteur de orl-1
AU2003235912A1 (en) 2002-05-10 2003-11-11 Taisho Pharmaceutical Co., Ltd. Spiro-ring compound
US6995168B2 (en) 2002-05-31 2006-02-07 Euro-Celtique S.A. Triazaspiro compounds useful for treating or preventing pain
AU2003268512A1 (en) 2002-09-09 2004-03-29 Janssen Pharmaceutica N.V. Hydroxy alkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders
WO2005016913A1 (fr) * 2003-08-19 2005-02-24 Pfizer Japan, Inc. Composes de tetrahydroisoquinoline ou d'isochroman en tant que ligands du recepteur orl-1 pour le traitement de la douleur et des troubles du systeme nerveux central
DE10360792A1 (de) 2003-12-23 2005-07-28 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
EP1732928A2 (fr) * 2004-03-29 2006-12-20 Pfizer, Inc. Composes acide propanoique beta piperidino methyle alpha aryle ou heteroaryle utilises comme antagonistes du recepteur orl1
DE102004039382A1 (de) * 2004-08-13 2006-02-23 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
EP2020414A1 (fr) 2007-06-20 2009-02-04 Laboratorios del Dr. Esteve S.A. Derivés spiro[piperidine-4,4'-thieno[3,2-c]pyran] et composés similaires en tant que inhibiteurs du recepteur sigma pour le traitement de pyschose
WO2009118173A1 (fr) 2008-03-27 2009-10-01 Grünenthal GmbH Dérivés de cyclohexane spirocycliques substitués

Also Published As

Publication number Publication date
TW201127841A (en) 2011-08-16
HN2012001011A (es) 2015-08-31
AU2010319581A1 (en) 2012-06-07
EP2501703B1 (fr) 2013-09-18
MY160665A (en) 2017-03-15
PL2501703T3 (pl) 2014-02-28
WO2011060035A1 (fr) 2011-05-19
ES2435814T3 (es) 2013-12-23
IL219370A0 (en) 2012-06-28
ECSP12011902A (es) 2012-07-31
EP2501703A1 (fr) 2012-09-26
US8232289B2 (en) 2012-07-31
DOP2012000135A (es) 2012-08-15
US20110118251A1 (en) 2011-05-19
DK2501703T3 (da) 2013-10-14
UA107943C2 (xx) 2015-03-10
PE20121430A1 (es) 2012-10-26
PT2501703E (pt) 2013-11-26
NZ600006A (en) 2014-05-30
RS53018B (sr) 2014-04-30
EA020848B1 (ru) 2015-02-27
AU2010319581C1 (en) 2014-05-15
KR20130026523A (ko) 2013-03-13
CR20130087A (es) 2013-04-17
EA201290352A1 (ru) 2012-10-30
CA2796161C (fr) 2015-03-17
SI2501703T1 (sl) 2013-11-29
CA2796161A1 (fr) 2011-05-19
CO6541545A2 (es) 2012-10-16
CN102612520B (zh) 2015-04-08
JP5680101B2 (ja) 2015-03-04
ZA201202967B (en) 2013-09-25
IL219370A (en) 2015-01-29
JO2887B1 (en) 2015-03-15
CN102612520A (zh) 2012-07-25
AU2010319581B2 (en) 2013-12-19
HK1169988A1 (en) 2013-02-15
TWI465453B (zh) 2014-12-21
MX2012005691A (es) 2012-06-13
KR101363830B1 (ko) 2014-02-14
HRP20130967T1 (hr) 2013-11-22
JP2013510859A (ja) 2013-03-28
AR078863A1 (es) 2011-12-07
ME01537B (me) 2014-04-20
PH12012500969A1 (en) 2013-01-07

Similar Documents

Publication Publication Date Title
PH12012500969A1 (en) Spiropiperidine compounds as orl-1 receptor antagonists
PT2501704E (pt) Compostos de espiropiperidina como antagonistas do receptor orl-1
JO2355B1 (en) Hereditary calcitonin polypeptide receptor antagonists
DE602008005771D1 (de) Disubstituierte alkyl-8-azabicycloä3.2.1üoktan-verbindungen als mu-opioid-rezeptorantagonisten
MA34650B1 (fr) Antagonistes du récepteur cgrp de pipéridinone carboxamide azaindane
ATE394400T1 (de) Bicyclische anilidspirohydantoine als cgrp- rezeptorantagonisten
ATE464305T1 (de) Bicyclische anilidspirolactame als antagonisten des cgrp-rezeptors
CY1111927T1 (el) Νεες ενωσεις ως διαμορφωτες υποδοχεα οπιοειδων
WO2006029153A3 (fr) Antagonistes de recepteurs cgrp d'anilide spirolactame monocyclique
MA31158B1 (fr) Composes tricycliques et leur utilisation comme modulateurs du recepteur de glucocorticoïdes
MA33178B1 (fr) Pipéridines substituées comme antagonistes de ccr3
WO2006031606A3 (fr) Carboxamide spirolactam cgrp receptor antagonists
ATE463245T1 (de) Tricyclische anilid-spirohydantoin-cgrp- rezeptorantagonisten
MA34300B1 (fr) Composés azotés hétérocycliques convenant comme inhibiteurs de la pde10
MY148544A (en) Pyridyl piperidine orexin receptor antagonists
JO3346B1 (ar) مواد مضادة C5aR
MA33155B1 (fr) Composes organiques et leurs utilisations
ATE517106T1 (de) Kondensierte spiropiperidine als modulatoren muskarinartiger rezeptoren
ATE537153T1 (de) Arylspirolactamverbindungen als antagonisten des cgrp-rezeptors
MA34377B1 (fr) Composé de pipéridinyle en tant que modulateur de l'activité des récepteurs des chimiokines
CH707539A8 (fr) Alliage d'or rose pour pièce d'horlogerie.
MA34545B1 (fr) Co-cristaux et sels d'inhibiteurs de ccr3
ATE518852T1 (de) Tricyclische anilid-spirohydantoin-cgrp- rezeptorantagonisten
GB2498268A (en) Silicone protectant compositions
DE602007004327D1 (de) Einen azepin-kern enthaltende antagonisten des histaminrezeptors